Sponsored by:
The Evolution of Antibody Drug Discovery: Unlocking Innovation with Bioinformatics and Al
Since monoclonal antibodies (mAbs) were developed and received their first approval, they became indispensable as research tools and biotherapeutic agents.
Since monoclonal antibodies (mAbs) were developed and received their first approval, they became indispensable as research tools and biotherapeutic agents. In the course of their evolution, mAbs have been used in new ways, such as adding drug payloads to create antibody-drug conjugates (ADCs), merging two antibodies to make bispecific antibodies (bsAbs), and creating custom biomolecules from antibody fragments. AI technologies are enhancing and accelerating monoclonal antibody (mAb) and related therapeutic development, though their success depends on access to substantial volumes of high-quality, relevant data.
This article will explore:
- The Pioneering First Approval
- Antibody Platforms Creating New Modalities
- Evolving the Research and Development Lifecycle with AI and Data Management.
- What’s Next for Antibody Development?
